Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Paclitaxel Plus Fruquintinib in Advanced Gastric Cancer
NCT07552402Recruiting
- Sponsor
- Harbin Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of paclitaxel oral solution and fruquintinib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Harbin Medical University. Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
paclitaxel oral solutionfruquintinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07552402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552402.